Study on CAR-T Therapy Followed by Bispecific Antibodies

Inclusion Criteria

• Have a life expectancy of at least 12 weeks.
• Have a history of relapsed or refractory large B-cell lymphoma, including transformed follicular lymphoma and follicular lymphoma Grade 3B, that has not responded to at least one previous standard treatment.
• Have no other available treatments expected to improve survival.
• Have had a PET/CT scan, CT scan, or MRI before CAR-T cell therapy showing at least one measurable tumor.
• Have a PET/CT scan, CT scan, or MRI after CAR-T cell therapy showing at least one measurable tumor.
• Be at least 30 days post-CAR-T cell infusion at the time of study enrollment.
• Have adequate lab test results.
• Be willing to use effective birth control methods.

Exclusion Criteria

• Have had severe cytokine release syndrome (CRS) or unresolved CRS after CAR-T therapy.
• Have had significant neurologic side effects or unresolved neurologic issues after CAR-T therapy.
• Cannot comply with study requirements, including hospital stays and activity restrictions.
• Are pregnant, breastfeeding, or planning to become pregnant during the study or shortly after.
• Have had a solid organ transplant.
• Have a history of autoimmune diseases like lupus or rheumatoid arthritis.
• Have had progressive multifocal leukoencephalopathy (PML).
• Have had severe allergic reactions to antibody treatments.
• Have other cancers that could interfere with the study.
• Have significant heart or lung diseases.
• Have active infections or recent major infections requiring hospitalization.
• Have had major surgery recently.
• Have received a live vaccine recently or plan to during the study.
• Have used certain immunosuppressive medications recently.
• Have a history of drug or alcohol abuse in the past year.
• Have any serious medical conditions that could affect participation in the study.